News by Subject
News by Disease
News by Date
Post Your News
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
US & Canada
Post an Event
News | News By Subject | News by Disease |
News By Date | Search News
Ther-Rx Corporation Announces the Availability of Clindesse® (Clindamycin Phosphate) Vaginal Cream, 2% for Prescribing
8/5/2013 9:35:00 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
ST. LOUIS, Aug. 5, 2013 -- /PRNewswire/ -- Ther-Rx Corporation, a women's health-focused pharmaceutical company and subsidiary of K-V Pharmaceutical Company (OTCQB Marketplace: KVPHQ/KVPBQ) announced today that Clindesse® (clindamycin phosphate) Vaginal Cream, 2% indicated for the treatment of bacterial vaginosis (BV) in non-pregnant women, is now available for prescribing. Wholesalers have ordered and received product and are distributing to retail pharmacies.
"We are pleased to be able to once again offer Clindesse," said Greg Divis, CEO of Ther-Rx and K-V. "Together with Gynazole-1®'s reintroduction in January, the availability of Clindesse represents a key positive milestone for the Company as the two products comprising our anti-infectives franchise are both available for prescribing."
Bacterial vaginosis (BV) is a complex polymicrobial infection that results from an overgrowth of a number of different bacterial species and is the most common vaginal infection in women of childbearing age. Clindesse has been used to treat 2.2 million women and is the first and only single-dose therapy approved for the treatment of BV in non-pregnant women.
Women with BV often self-diagnose and try over-the-counter anti-fungal creams used for yeast infections, which are not effective in treating BV. According to one study published in 2002 of women seeking OTC treatments for self-diagnosed yeast infections, 66% of women had misdiagnosed their condition, which reinforces the importance of being examined by a healthcare provider to diagnose and determine the appropriate treatment.
"Women experiencing vaginal infections are eager for treatments that provide fast relief from symptoms and convenience in dosing and administration," said Michael Randell, M.D., an Obstetrician and Gynecologist at Northside Hospital in Atlanta, Georgia. "Clindesse and Gynazole-1 are well-established treatment options with high patient satisfaction, so it's great to be able to prescribe them for my patients again."
Healthcare providers can find more information at www.clindesse.com and www.gynazole-1.com or by calling Ther-Rx customer service at (877) 567-7676.
Important Safety Information for Clindesse® (clindamycin phosphate) Vaginal Cream, 2%
You should not use Clindesse if you have had an allergic reaction to clindamycin or other drugs in this class (lincosamides). Allergic reactions to other drugs containing clindamycin have included rash, hives, and life-threatening allergic reactions (anaphylaxis). You should not use Clindesse if you have certain bowel diseases, including Crohn's disease (regional enteritis), ulcerative colitis, or a history of Clostridium difficile-associated diarrhea (CDAD).
CDAD has been reported with nearly all antibiotics, including clindamycin. CDAD may range from mild diarrhea to a fatal inflammation of the colon. Contact your healthcare provider if you experience diarrhea following antibiotic use.
Clindesse contains mineral oil. Mineral oil may weaken latex or rubber products such as condoms or vaginal contraceptive diaphragms. Due to this, the use of these contraceptives is not recommended during treatment with Clindesse or for 5 days following treatment. During this time period, condoms may not work reliably to prevent pregnancy or to protect against HIV and other sexually transmitted diseases.
Vaginal intercourse or use of other vaginal products is not recommended for at least 7 days following treatment with Clindesse.
The most common side effects of Clindesse are yeast infections, headache, back pain, constipation, and urinary tract infection.
Full prescribing information can be viewed at www.clindesse.com/PDF/PI.pdf.
Important Safety Information for Gynazole-1 (Butoconazole Nitrate Vaginal Cream USP, 2%)
You should not use Gynazole-1 if you have had an allergic reaction to butoconazole or other ingredients in this cream.
Gynazole-1 contains mineral oil. Mineral oil may weaken latex or rubber products such as condoms or vaginal contraceptive diaphragms. Due to this, the use of these contraceptives is not recommended during Gynazole-1 treatment or for 3 days following treatment. During this time period, condoms may not work reliably to prevent pregnancy or to protect against HIV and other sexually transmitted diseases.
The most common side effects of Gynazole-1 are vulvar/vaginal burning, itching, soreness and swelling, and pelvic or abdominal pain or cramping.
Be sure to talk to your doctor if your yeast infection does not get better or you experience frequent yeast infections. Frequent yeast infections, especially those that are difficult to treat, may be caused by another more serious health problem, like a weakened immune system.
Full prescribing information can be viewed at www.gynazole-1.com/PI.PDF.
To report negative side effects, contact Ther-Rx Corporation at 1-877-567-7676 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
About Ther-Rx Corporation
Ther-Rx Corporation, a subsidiary of K-V Pharmaceutical Company, is a specialty branded pharmaceutical company with a primary focus in the area of women's healthcare. As such, we are committed to advancing the health of women across all the stages of their lives.
For further information about K-V Pharmaceutical Company, please visit the Company's corporate website at www.kvpharmaceutical.com.
Help employers find you! Check out all the jobs and post your resume.